Inari Medical, Inc. (NASDAQ:NARI) Receives Consensus Rating of "Hold" from Analysts

Inari Medical, Inc. (NASDAQ:NARI - Get Free Report) has received an average rating of "Hold" from the twelve research firms that are presently covering the stock, Marketbeat reports. Ten analysts have rated the stock with a hold rating and two have issued a buy rating on the company. The average 1-year target price among brokerages that have issued ratings on the stock in the last year is $68.00.

Several equities research analysts have issued reports on NARI shares. Robert W. Baird reissued a "neutral" rating and issued a $80.00 price target (down previously from $81.00) on shares of Inari Medical in a report on Tuesday. Wells Fargo & Company reaffirmed an "equal weight" rating and issued a $80.00 price target (up previously from $65.00) on shares of Inari Medical in a research note on Tuesday. Needham & Company LLC reiterated a "hold" rating on shares of Inari Medical in a research note on Tuesday, October 29th. Stifel Nicolaus started coverage on shares of Inari Medical in a research note on Tuesday, September 17th. They issued a "hold" rating and a $50.00 target price on the stock. Finally, Oppenheimer began coverage on shares of Inari Medical in a research report on Tuesday, December 17th. They set an "outperform" rating and a $75.00 target price for the company.

Insider Transactions at Inari Medical

In other news, Director William Hoffman sold 40,000 shares of the company's stock in a transaction on Wednesday, October 16th. The stock was sold at an average price of $45.02, for a total transaction of $1,800,800.00. Following the transaction, the director now owns 601,233 shares of the company's stock, valued at $27,067,509.66. This represents a 6.24 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Andrew Hykes sold 3,000 shares of the firm's stock in a transaction dated Friday, December 20th. The shares were sold at an average price of $55.29, for a total value of $165,870.00. Following the completion of the transaction, the chief executive officer now owns 439,310 shares in the company, valued at approximately $24,289,449.90. This represents a 0.68 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 206,000 shares of company stock worth $10,527,870. Corporate insiders own 10.60% of the company's stock.

Institutional Investors Weigh In On Inari Medical

A number of institutional investors and hedge funds have recently modified their holdings of the business. Aigen Investment Management LP acquired a new stake in Inari Medical during the 3rd quarter worth $428,000. Vestal Point Capital LP boosted its position in shares of Inari Medical by 342.9% in the 3rd quarter. Vestal Point Capital LP now owns 1,550,000 shares of the company's stock worth $63,922,000 after purchasing an additional 1,200,000 shares during the last quarter. Lighthouse Investment Partners LLC acquired a new stake in shares of Inari Medical during the second quarter worth $2,145,000. Dynamic Technology Lab Private Ltd bought a new stake in Inari Medical in the third quarter valued at about $1,397,000. Finally, Verition Fund Management LLC acquired a new position in Inari Medical in the third quarter valued at about $1,235,000. 90.98% of the stock is owned by institutional investors.

Inari Medical Stock Performance

Shares of NASDAQ:NARI traded up $14.45 during trading on Tuesday, hitting $79.45. 24,469,891 shares of the stock were exchanged, compared to its average volume of 9,994,396. The company has a market capitalization of $4.65 billion, a price-to-earnings ratio of -58.85 and a beta of 0.97. Inari Medical has a 1-year low of $36.73 and a 1-year high of $79.50. The company's fifty day simple moving average is $52.85 and its 200-day simple moving average is $48.92.

Inari Medical Company Profile

Inari Medical, Inc builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation.